medac GmbH
http://www.medac.de
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From medac GmbH
Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma
Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.
Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field
Ono’s just-announced purchase of Deciphera has put the tenosynovial giant cell tumor space under the spotlight and SynOx is making strides to stay at the head of the pack helped by significant financing.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
BMS Fast Tracks CAR-T Manufacturing With Cellares Deal
In a partnership worth $380m, BMS has reserved clinical and commercial capacity with Cellares, a company whose $255m series C round it participated in last year.
Company Information
- Industry
- In Vitro Diagnostics
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
-
- medac Gesellschaft für klinische Spezialpräparate mbH
- medac GmbH Sp. z o.o.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice